Peroxidases have more functions than a Swiss army knife

Plant peroxidases (class III peroxidases) are present in all land plants. They are members of a large multigenic family. Probably due to this high number of isoforms, and to a very heterogeneous regulation of their expression, plant peroxidases are involved in a broad range of physiological processes all along the plant life cycle. Due to two possible catalytic cycles, peroxidative and hydroxylic, peroxidases can generate reactive oxygen species (ROS) (•OH, HOO•), polymerise cell wall compounds, and regulate H2O2 levels. By modulating their activity and expression following internal and external stimuli, peroxidases are prevalent at every stage of plant growth, including the demands that the plant meets in stressful conditions. These multifunctional enzymes can build a rigid wall or produce ROS to make it more flexible; they can prevent biological and chemical attacks by raising physical barriers or by counterattacking with a large production of ROS; they can be involved in a more peaceful symbiosis. They are finally present from the first hours of a plant's life until its last moments. Although some functions look paradoxical, the whole process is probably regulated by a fine-tuning that has yet to be elucidated. This review will discuss the factors that can influence this delicate balanc

The Helium Cryogenic System for the ATLAS Experiment

The magnetic configuration of the ATLAS detector is generated by an inner superconducting solenoid and three air-core toroids (the barrel and two end-caps), each of them made of eight superconducting coils. Two separated helium refrigerators will be used to allow cool-down from ambient temperature and steady-state operation at 4.5 K of all the magnets having a total cold mass of about 600 tons. In comparison with the preliminary design, the helium distribution scheme and interface with the magnet sub-systems are simplified, resulting in a considerable improvement of the operational easiness and the overall reliability of the system at some expense of the operational flexibility. The paper presents the cryogenic layout and the basic principles for magnets cool-down, steady state operation and thermal recovery after a fast energy dump

Cryogenics for the Large Hadron Collider Experiments

High Energy Physics experiments have frequently adopted cryogenic versions of their apparatus to achieve the desired performance. Among the four new experiments for the CERN Large Hadron Collider (LHC) the two largest, ATLAS and CMS, include spectrometers using 4.5 K superconducting magnets and detectors filled with liquid argon at 87 K, respectively for particle momentum and energy measurements. These detectors are of unprecedented size and complexity and the definition of the associated cryogenic systems is the result of a collaboration between CERN and several external institutes all around the world. A review of the various systems is presented with particular emphasis to the basic cooling principles, the special cryogenic features and the operation scenarios

The CERN Cryogenic Test Facility for the Atlas Barrel Toroid Magnets

The superconducting magnet system of the ATLAS detector will consist of a central solenoid, two end-cap toroidal magnets (ECT) and the barrel toroid magnet (BT) made of eight coils symmetrically placed around the central axis of the detector. The magnets will be tested individually in a 5000 m2 experimental area prior to their final installation at an underground cavern of the LHC Collider. For the BT magnets, a dedicated cryogenic test facility has been designed which is currently under the construction and commissioning phase. A liquid nitrogen pre-cooling unit and a 1200 [email protected] refrigerator will allow flexible operating conditions via a rather complex distribution and transfer line system. Flow of two-phase helium for cooling the coils is provided by centrifugal pumps immersed in a saturated liquid helium bath. The integration of the pumps in an existing cryostat required the adoption of novel mechanical solutions. Tests conducted permitted the validation of the technical design of the cryostat and its instrumentation. The characteristics of one pump were measured and pressure rise of 300 mbar at nominal flow of 80 g/s confirmed the specifications

Refrigeration System for the ATLAS Experiment

The proposed ATLAS detector for the 27 km circumference LHC collider is of unprecedented size and complexity. The magnet configuration is based on an inner superconducting solenoid and large superconducting air-core toroids (barrel and two end-caps) each made of eight coils symmetrically arranged outside the calorimetry. The total cold mass approaches 600 tons and the stored energy is 1.7 GJ. The cryogenic infrastructure will include a 6 kW @ 4.5 K refrigerator, a precooling unit and distribution systems and permits flexible operation during cool-down, normal running and quench recovery. A dedicated LN2 refrigeration system is proposed for the three liquid argon calorimeters (84 m3 of LAr). Magnets and calorimeters will be individually tested prior to their definitive installation in a large scale cryogenic test area on the surface. The experiment is scheduled to be operational in 2005

Cryogenics for CERN experiments: past, present and future

Use of cryogenics at CERN was originated (in the 1960s) by bubble chambers and the associated s.c. solenoids. Complex cryoplants were installed to provide cooling at LH2 and LHe temperatures. Continuity (in the 1970s) in He cryogenics for experiments was provided by spectrometer magnets for fixed target physics of the SPS accelerator. More recently (in the 1980s), large "particle-transparent" s.c. solenoids for collider experiments (LEP) have been built demanding new cryoplants. The LHC experiments (in the 2000s) will continue the tradition with s.c. dipoles (ALICE and LHCb), solenoids (CMS, ATLAS) and toroids (ATLAS) of unusual size. Cryogenics for experiments using noble liquids follows the same trend since the development (in the 1970s) of the first shower LAr detectors. A LKr calorimeter (about 10 m3) will be operated in 1996 and the ATLAS experiment foresees a set of three huge LAr calorimeters (almost 90 m3 total volume of liquid) to be installed underground

Melanoma metastasis mimicking gastric cancer: a challenge that starts from diagnosis

The gastrointestinal tract is an uncommon site of metastasis in melanoma. However, when the primary melanoma cannot be found, the diagnosis of gastric melanoma by endoscopic biopsy is problematic mainly because some tumors are amelanotic and do not contain melanin granules detectable by microscopy. A 56-year-old Caucasian man with melanoma was referred to us following an initial histopathological diagnosis via gastroscopy of poorly differentiated primary gastric carcinoma. A computerized tomography (CT) scan showed metastatic disease and on the basis of this information we started palliative chemotherapy. However, the atypical presentation of the disease with subcutaneous metastases prompted us to make a more in-depth evaluation. Immunohistochemical evaluation modified the diagnosis to melanoma. After only one cycle of chemotherapy, treatment was changed to dabrafenib + trametinib, which was better tolerated and initially induced a partial response. The patient is currently in good clinical condition 20 months after diagnosis. Our case report highlights the difficulty in diagnosing melanoma of the gastrointestinal tract and indicates the need for pathologists and clinicians to consider such a possibility when they are faced with a diagnosis of poorly differentiated gastric cancer and unusual sites of metastasis

Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy

The incidence of squamous cell carcinoma of the anal canal (SCAC) is increasing in both sexes but the standard treatment remains that of 20 years ago. However, interesting data have recently emerged on the use of anti-epidermal growth factor receptor (EGFR) agents and immunotherapy in advanced disease. Thus, new avenues of research are opening up that will hopefully lead to more effective therapeutic strategies. We provide an overview of the latest studies published on this tumor and discuss the possible future therapeutic options for combination therapy, anti-EGFR treatment and radiotherapy

The ATLAS magnet test facility at CERN

The magnet system for the ATLAS detector at CERN consists of a Barrel Toroid (BT), two End-Cap Toroids (ECT) and a Central Solenoid (CS). The overall dimensions of the system are 20 m in diameter by 26 m in length. Before underground installation all coils will be tested on surface in a magnet test facility which is under construction. Moreover two model coils are tested as well as subsystems. In this paper the design and construction of the test facility is presented. (3 refs)

Chemoradiotherapy (Gemox plus helical tomotherapy) for unresectable locally advanced pancreatic cancer: A phase II study

The aim of the study was to evaluate the safety and efficacy of a new chemo-radiotherapy regimen for patients with locally advanced pancreatic cancer (LAPC). Patients were treated as follows: gemcitabine 1000 mg/m2 on day 1, and oxaliplatin 100 mg/m2 on day 2, every two weeks (GEMOX regimen) for 4 cycles, 15 days off, hypofractionated radiotherapy (35 Gy in 7 fractions in 9 consecutive days), 15 days off, 4 additional cycles of GEMOX, restaging. From April 2011 to August 2016, a total of 42 patients with non resectable LAPC were enrolled. Median age was 67 years (range 41\u201375). Radiotherapy was well tolerated and the most frequently encountered adverse events were mild to moderate nausea and vomiting, abdominal pain and fatigue. In total, 9 patients underwent surgical laparotomy (5 radical pancreatic resection 1 thermoablation and 3 explorative laparotomy), 1 patient became operable but refused surgery. The overall resectability rate was 25%, while the R0 resection rate was 12.5%. At a median follow-up of 50 months, the median progression-free survival and overall survival were 9.3 (95% CI 6.2\u201314.9) and 15.8 (95% CI 8.2\u201323.4) months, respectively. The results demonstrate the feasibility of a new chemo-radiotherapy regimen as a potential treatment for unresectable LAPC